Results 171 to 180 of about 1,055,467 (319)

Therapeutics

International Journal of Clinical Practice, 1957
openaire   +3 more sources

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

The expanding role of protease therapeutics (2012-2026): from replacement therapies to immune system modulation and beyond. [PDF]

Biochem J
Nelson SE, Martinusen SG, Pho R, Long LF, Denard CA.   +4 more
europepmc   +1 more source

Therapeutics Letter 49

, 2003
Therapeutics Letter 49 discusses optimal dosing strategies for statins for secondary prevention. Conclusions: Statins provide a cardiovascular and total mortality benefit for patients with clinically evident occlusive vascular disease (secondary ...
Therapeutics Initiative (University of British Columbia)
core  

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia. [PDF]

Genome Biol
Rathgeber AC, Fernandes SM, Nagler A, Li S, Dorfman DM, Bullinger L, Davids MS, Brown JR, Livak KJ, Ludwig LS, Wu CJ, Penter L.   +11 more
europepmc   +1 more source

Therapeutics Letter 32

, 1999
Therapeutics Letter 32 reviews the management of erectile dysfunction. Conclusions: Inquire about erectile dysfunction in all adult males as a potential early indicator of modifiable factors.
Therapeutics Initiative (University of British Columbia)
core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. [PDF]

J Immunother Cancer
Naing A, Lin CC, Patel MR, Curigliano G, Burris HA, Thistlethwaite F, De Braud F, Minchom A, Ascierto PA, Wake M, Nguyen MA, Abbadessa G, Sainson RCA, Palu CC, Quaratino S, Deantonio C.   +15 more
europepmc   +1 more source

Therapeutics Letter 88

, 2013
Therapeutics Letter 88 explores the use of pragmatic randomized trials as a means of addressing gaps in evidence. Compared to efficacy trials, pragmatic (effectiveness) trials are intended to answer the questions that clinicians and patients have ...
Therapeutics Initiative (University of British Columbia)
core